ArticleScientific reports2025
Biosynthesis and activity of Zn-MnO nanocomposite in vitro with molecular docking studies against multidrug resistance bacteria and inflammatory activators.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Synergistic antimicrobial and antibiofilm effects of mycosynthesized MnO-MgO bimetallic nanoparticles against drug-resistant pathogens.BMC microbiology · 2026Article
- Advanced Biomaterials for Restorative Dentistry: From Biocompatibility to Bioactive and Smart Materials.Bioengineering (Basel, Switzerland) · 2026Review
- Therapeutic potential of infrared-treated bee venom: enhanced multi-faceted bioactivity via compositional modulation.Bioresources and bioprocessing · 2026Article
- Green Synthesis of ZnO Nanoparticles From Spirulina platensis: Antimicrobial and Cytotoxic Evaluation With Molecular Docking Studies.ChemistryOpen · 2026Article
- Fungal-mediated green synthesis of ZnO-MnO nanocomposites with antimicrobial and anticancer properties.Scientific reports · 2026Article
- Antibacterial potential, DNA binding and molecular docking investigations of newly green synthesized zinc oxide/chitosan/vancomycin nanocomposite using Bacillus licheniformis ATCC 4527 against some drug-resistant bacteria.Microbial cell factories · 2026Article
- Eco-friendly biosynthesis of manganese oxide-silver bimetallic nanoparticles using Cucumis melo peel extract: characterization, antioxidant, antimicrobial, and antiviral activities.Bioresources and bioprocessing · 2026Article
- Green-synthesized ZnO-MnO nanocomposite as a potent antimicrobial and antibiofilm agent: protein leakage mechanism and synergistic interaction with cefotaxime.Frontiers in microbiology · 2026Article
- Innovative vaginal wash formulation with Chitosan nanoparticles targets microbial pathogens, ovarian cancer and inflammation.Scientific reports · 2025Article
- The potential of Eco-friendly synthesis of multifunctional ZnO-CuO nanocomposites using Mentha longifolia extract for their biomedical applications.Journal of materials science. Materials in medicine · 2025Article
- Ozone-Assisted Green Upgrading ofFoods (Basel, Switzerland) · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the green synthesis of Zn-MnO nanocomposites via the fungus Penicillium rubens. Herein, the synthesized Zn-MnO nanocomposites were confirmed by UV-spectrophotometry with a top peak (370 nm). Transmission electron microscopy confirmed irregular particles with a spherical-like shape ranging from 25.13 to 36.21 nm. Numerous functional groups were detected on the surface of Zn-MnO nanocomposite via Fourier-transform infrared spectroscopy. X-Ray diffraction assay appeared that the synthesized Zn-MnO nanocomposites contained two different components, MnO (JCPDS 81-2261) and ZnO (JCPDS 36-1451), while energy dispersive X-ray spectra confirmed the occurrence of manganese, zinc, oxygen, and carbon in Zn-MnO nanocomposites. Zn-MnO nanocomposites demonstrated excellent suppress effect versus the growth of various bacteria namely Staphylococcus aureus, Methicillin-resistant S. aureus (MRSA), Salmonella typhi, and Klebsiella pneumoniae via agar well diffusion assays with inhibition areas of 36 ± 0.1, 25 ± 0.1, 27 ± 0.2, and 23 ± 0.2 mm, correspondingly. Alterations in the ultrastructure of the treated K. pneumoniae by Zn-MnO nanocomposite were recorded. Both the values of minimum inhibitory concentration (MIC) and minimum bactericidal concentration of Zn-MnO nanocomposite extended from 15.62 to 125 µg/mL employing the examined bacteria. The antibiofilm activity of Zn-MnO nanocomposites was 82.07, 75.43, 43.65, and 41.35% at 25% MIC, and 96.54, 93.0, 94.53, and 91.11% at 75% MIC against S. aureus, MRSA, K. pneumoniae, and S. typhi, respectively. At 25 to 75% MIC, Zn-MnO nanocomposites exhibited antihemolytic activity with the maximum activity of 96.3% at 75% MIC in the presence of MRSA. Extensive molecular docking studies were performed to identify the optimal location for manganese oxide and zinc oxide nanoclusters binding to MRSA. MnO-NPs and ZnO-NPs demonstrated inhibitory activity against the crystal structure of putative minohydrolase (PDB ID: 4EWT), methicillin acyl-penicillin binding protein 2a structure (PDB ID: 1MWU) and K2U bound crystal structure of class II peptide deformylase from MRSA (PDB ID: 6JFQ). The minimum binding energy was utilized to estimate the receptor's binding site with NPs, providing additional understanding of the ways of action. Anti-inflammatory activity of Zn-MnO nanocomposites via cyclooxygenase-1 and cyclooxygenase-2 enzymes inhibition was documented with IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.